Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Berlin

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Gastroenterology|August 1, 1989
MK-329 has no direct effect on the pancreasR G Berlin
Digestive Diseases and Sciences|February 1, 1991
Omeprazole. Gastrin and gastric endocrine cell data from clinical studiesR G Berlin
The Western Journal of Medicine|March 1, 1986
Metoclopramide-induced reversible impotenceR G Berlin
Lancet (London, England)|December 19, 1987
Famotidine does not have a negative inotropic effectR G Berlin
Gastroenterology|June 1, 1990
Famotidine is devoid of negative inotropic effectR G Berlin
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 1, 1989
Disulfiram hepatotoxicity: a consideration of its mechanism and clinical spectrumR G Berlin
Digestive Diseases and Sciences|October 1, 1991
Omeprazole: gastrin and gastric data (August 1991)R G Berlin
Alimentary Pharmacology & Therapeutics|April 1, 1991
Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcerR G Berlin, J K Root, T J Cook
The American Journal of Medicine|October 24, 1986
Famotidine: an appraisal of its mode of action and safetyR G Berlin, B V Clineschmidt, J A Majka
Scandinavian Journal of Gastroenterology|May 1, 1993
Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study GroupT J Simon, R G Berlin, R Tipping, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Gastroenterology|August 1, 1989
MK-329 has no direct effect on the pancreasR G Berlin
Digestive Diseases and Sciences|February 1, 1991
Omeprazole. Gastrin and gastric endocrine cell data from clinical studiesR G Berlin
The Western Journal of Medicine|March 1, 1986
Metoclopramide-induced reversible impotenceR G Berlin
Lancet (London, England)|December 19, 1987
Famotidine does not have a negative inotropic effectR G Berlin
Gastroenterology|June 1, 1990
Famotidine is devoid of negative inotropic effectR G Berlin
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 1, 1989
Disulfiram hepatotoxicity: a consideration of its mechanism and clinical spectrumR G Berlin
Digestive Diseases and Sciences|October 1, 1991
Omeprazole: gastrin and gastric data (August 1991)R G Berlin
Alimentary Pharmacology & Therapeutics|April 1, 1991
Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcerR G Berlin, J K Root, T J Cook
The American Journal of Medicine|October 24, 1986
Famotidine: an appraisal of its mode of action and safetyR G Berlin, B V Clineschmidt, J A Majka
Scandinavian Journal of Gastroenterology|May 1, 1993
Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study GroupT J Simon, R G Berlin, R Tipping, et al.
Pageof 2